Platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer
Key Notes
FDA approved Lifyorli (relacorilant) plus nab-paclitaxel on March 25, 2026, ahead of the original PDUFA target of July 11, 2026. First approval for Corcept lead compound. Based on the Phase 3 ROSELLA trial (n=381), which met overall survival and PFS endpoints in platinum-resistant ovarian cancer after 1 to 3 prior lines including bevacizumab. Selective glucocorticoid receptor antagonist. Source: FDA and Corcept press release (March 25, 2026).
⚠️ Not Investment Advice: This information is provided for educational purposes only.
PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period,
issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on
historical base rates and do not account for drug-specific factors. Always consult a financial advisor
before making investment decisions.
Discussion
Share your analysis, research, or questions about this catalyst. No account required.